This Reporting Protocol describes data collection for influenza, COVID-19, and other respiratory viruses (such as RSV or new viruses of public health concern) in the EU/EEA and wider WHO European Region. Data collection is integrated for most datasets in line with the operational considerations for respiratory virus surveillance in Europe.
Joint statement by the European Centre for Disease Prevention and Control, European Chemicals Agency, European Environment Agency, European Food Safety Authority and European Medicines Agency.
This document presents the core protocol for ECDC studies of CVE and IVE against symptomatic laboratory-confirmed influenza or SARS-CoV-2 infection, respectively, at primary care level.
High levels of community transmission and the co-circulation of respiratory viruses, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza, respiratory syncytial virus (RSV) and others can increase pressure on healthcare systems.
Since the risk assessment published by ECDC in August 2021 on the risk of vCJD disease transmission via blood and PDMP manufactured from donations obtained in the UK, no new cases of vCJD associated with dietary exposure or transfusion of blood or blood components have been reported in EU/EEA or in the rest of the world.
This Reporting Protocol contains guidelines on how to prepare data for submission to TESSy, deadlines for data submission, subject-specific information, and links to further information.
This document outlines operational considerations to support the continuity of national surveillance systems and public health laboratories for epidemiological and virological surveillance for influenza, SARS-CoV-2, and potentially other respiratory viruses in the 2022/2023 winter season and beyond.
The Protocol is targeted at the national public health reference laboratories to guide the susceptibility testing needed for EU surveillance and the reporting to ECDC.
This document provides laboratories with a single protocol for producing recombinant full-length hamster prion protein and using it to perform the Real-Time Quaking-Induced Conversion assay (RT-QuIC), which can distinguish sporadic Creutzfeldt-Jakob disease (sCJD) from variant Creutzfeldt-Jakob disease (vCJD).
This document outlines operational considerations for how to support the continuity of national influenza surveillance systems and public health laboratories for the epidemiological and virological surveillance for influenza in the 2020–2021 season during the ongoing COVID-19 pandemic.